De Marchi S, Cecchin E
Department of Internal Medicine, University of Udine, Medical School, Italy.
Nephrol Dial Transplant. 1991;6(2):79-85. doi: 10.1093/ndt/6.2.79.
The purpose of this study was to investigate the significance of serum antithyroid antibodies in Alport's syndrome. Thyroid microsomal and thyroglobulin antibodies were assessed in three families with Alport's syndrome for a total of 11 patients and 17 healthy relatives, as well as in 40 haemodialysis patients and in 40 healthy subjects. Thyroid function tests, including the measurement of serum total thyroxine (TT4), total triiodothyronine (TT3), free thyroxine (fT4) and free triiodothyronine (fT3) concentrations, and thyrotropin-releasing hormone (TRH) stimulation tests were performed in all patients and subjects. Among patients with Alport's syndrome, five (45%) had elevated titres of thyroid microsomal antibodies and eight (73%) had positive titres of thyroglobulin antibodies, whereas only one healthy relative (6%) had circulating antithyroid antibodies. Fine-needle aspiration biopsy of the thyroid demonstrated a lymphocytic infiltration that indicated the existence of asymptomatic autoimmune thyroiditis in all five patients with elevated thyroid microsomal antibody titres. The prevalence of antithyroid antibodies in healthy subjects and in haemodialysis patients was 7.5% and 12.5% respectively. Functional tests demonstrated a thyroid dysfunction in four of five patients with asymptomatic autoimmune thyroiditis. Two patients had evidence of subclinical hypothyroidism. Two other patients, both with end-stage renal failure, showed a blunted TSH response to TRH, increased fT4 and elevated borderline fT3. The present study indicates that elevated titres of serum antithyroid antibodies may be detected in patients with Alport's syndrome. These patients are at risk of developing asymptomatic autoimmune thyroiditis and thyroid dysfunction. Subclinical hypothyroidism and, perhaps, preclinical hyperthyroidism may be found in these patients.
本研究的目的是探讨血清抗甲状腺抗体在Alport综合征中的意义。对三个患有Alport综合征的家庭中的11例患者和17名健康亲属,以及40例血液透析患者和40名健康受试者进行了甲状腺微粒体抗体和甲状腺球蛋白抗体检测。对所有患者和受试者进行了甲状腺功能测试,包括血清总甲状腺素(TT4)、总三碘甲状腺原氨酸(TT3)、游离甲状腺素(fT4)和游离三碘甲状腺原氨酸(fT3)浓度的测定,以及促甲状腺激素释放激素(TRH)刺激试验。在Alport综合征患者中,5例(45%)甲状腺微粒体抗体滴度升高,8例(73%)甲状腺球蛋白抗体滴度呈阳性,而只有1名健康亲属(6%)有循环抗甲状腺抗体。甲状腺细针穿刺活检显示淋巴细胞浸润,表明所有5例甲状腺微粒体抗体滴度升高的患者均存在无症状自身免疫性甲状腺炎。健康受试者和血液透析患者中抗甲状腺抗体的患病率分别为7.5%和12.5%。功能测试显示,5例无症状自身免疫性甲状腺炎患者中有4例存在甲状腺功能障碍。2例患者有亚临床甲状腺功能减退的证据。另外2例均为终末期肾衰竭的患者,TSH对TRH的反应迟钝,fT4升高,fT3临界值升高。本研究表明,Alport综合征患者可能检测到血清抗甲状腺抗体滴度升高。这些患者有发生无症状自身免疫性甲状腺炎和甲状腺功能障碍的风险。这些患者可能会出现亚临床甲状腺功能减退,或许还会出现临床前期甲状腺功能亢进。